Innovative therapeutic approaches for hereditary neuromuscular diseases

Der Nervenarzt
J Kirschner, B Schoser

Abstract

Advances in the understanding of the genetic mechanisms and pathophysiology of neuromuscular diseases have recently led to the development of new, innovative and often mutation-specific therapeutic approaches. Methods used include splicing modification by antisense oligonucleotides, read-through of premature stopcodons, use of viral vectors to introduce genetic information, or optimizing the effectiveness of enzyme replacement therapies. The first drugs have already been approved for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. For other diseases, such as myotubular myopathy, myotonic dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease, new promising approaches are in preclinical or clinical development. As these are rare diseases with a broad spectrum of clinical severity, drug approval is often based on a limited amount of evidence. Therefore, systematic follow-up in the postmarketing period is particularly important to assess the safety and efficacy of these new and often high-priced orphan drugs.

References

Mar 4, 2003·Nature Reviews. Molecular Cell Biology·Pradipta GhoshStuart Kornfeld
Mar 12, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yunxiang ZhuSeng H Cheng
Jan 28, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Cathryn S MahBarry J Byrne
Mar 10, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haiyan FuDouglas M McCarty
Aug 3, 2013·Annals of Neurology·Jerry R MendellUNKNOWN Eteplirsen Study Group
Jan 21, 2014·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Dwight D KoeberlPriya S Kishnani
May 28, 2014·Human Molecular Genetics·Zizhen YaoStephen J Tapscott
Jun 19, 2014·Skeletal Muscle·Rabi TawilStephen J Tapscott
Jul 22, 2014·Muscle & Nerve·Katharine BushbyUNKNOWN PTC124-GD-007-DMD STUDY GROUP
Jul 24, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Giancarlo ParentiGeneroso Andria
Sep 23, 2014·Human Gene Therapy. Clinical Development·Principal Investigators Barry J ByrneLee Ann Lawson
Jan 28, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ellen L van AgtmaalBé Wieringa
Sep 13, 2017·Hematology/oncology Clinics of North America·Takis AthanasopoulosRafael J Yáñez-Muñoz
Nov 2, 2017·The New England Journal of Medicine·Jerry R MendellBrian K Kaspar
Nov 2, 2017·The New England Journal of Medicine·Richard S FinkelUNKNOWN ENDEAR Study Group
Dec 6, 2017·Neuromuscular Disorders : NMD·Nathalie GoemansUNKNOWN DEMAND III study group
Feb 2, 2018·Molecular Therapy. Methods & Clinical Development·Lindsay M WallaceScott Q Harper
Feb 15, 2018·The New England Journal of Medicine·Eugenio MercuriUNKNOWN CHERISH Study Group
Apr 25, 2018·Journal of Neuromuscular Diseases·Astrid PechmannJanbernd Kirschner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

The Lancet Child & Adolescent Health
Mariacristina ScotoFrancesco Muntoni
The American Journal of Nursing
Diane S Aschenbrenner
European Journal of Human Genetics : EJHG
Annemieke Aartsma-Rus, Gert-Jan B van Ommen
NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics
Lisa J Bain
© 2022 Meta ULC. All rights reserved